Callan JMB Advances IV Bag Manufacturing Facility with Projected $450 Million in Annual Revenue
Key Highlights
- ➤$16 million IV bag facility approved at Atlas Complex in Alabama
- ➤Facility projected to generate $450 million annual revenue once operational
- ➤Standard IV bags projected to contribute $300 million annual revenue
- ➤Premixed drug IV bags projected to contribute $150 million annual revenue
- ➤Blueprint approval advances Callan JMB’s domestic pharmaceutical manufacturing strategy
Expert Statements
Wayne Williams, Chief Executive Officer of Callan JMB
“The commercial objective is clear: build improved domestic manufacturing capacity for essential IV products and support it with the logistics, quality controls, and distribution capabilities needed to serve healthcare customers.”
Wayne Williams, Chief Executive Officer of Callan JMB
“Approving the blueprints is a concrete step toward that objective. This project builds on our healthcare logistics and emergency-preparedness experience while supporting the strengthening of the United States (U.S.) domestic pharmaceutical production, enhancing U.S. supply chain resilience, and improving national security through medical preparedness.”
Planned $16 million facility at the Atlas Complex advances Callan JMB’s pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness
SPRING BRANCH, Texas, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified preparedness, logistics, and critical-infrastructure company, today announced formal approval of blueprints for the planned $16 million intravenous (IV) bag manufacturing and distribution facility at the Atlas Complex in Marion, Alabama. Once in production, the facility is projected to generate $450 million in annual revenue, including $300 million from standard IV bags and $150 million from premixed drug IV bags.
Get started
Create a free account to read the full story.